Authorized purpose: Lumify is a general-purpose ultrasound system using compatible Android devices and USB transducers; K232500 adds AI-assisted automatic ejection-fraction quantification.
Clinical role
Ultrasound acquisition, measurement, analysis, reporting, and release-specific AI assistance.
Images and patients
Ultrasound · Multi-region
Key limitation
Keep in mind: Auto EF Quantification feature will be available on version 5.0 (Android) of Lumify Diagnostic Ultrasound System. Auto EF is a new Artificial Intelligence (AI) feature available on the S4-1 transducer in the Cardiac Preset on the Lumify application based on the LVivo EF algorithm. It provides automated assessment of the LV EF supporting evaluation from only apical four chamber (A4CH) view.
Clinical detailsPurpose, workflow fit, evidence, and safety record
Workflow navigation pilot
Workflow role has not yet been reviewed for this navigation pilot.
A tag identifies a documented role; it does not establish compatibility or local acceptance. Methods and sources
What does this software do?Authorized purpose: Lumify is a general-purpose ultrasound system using compatible Android devices and USB transducers; K232500 adds AI-assisted automatic ejection-fraction quantification.
Which images or clinical context are in scope?Modality: Ultrasound Anatomy or clinical context: Multi-region Input: The Philips Lumify Diagnostic Ultrasound System (Lumify) is a mobile, durable, and reusable, software-controlled medical device, which is intended to acquire high-resolution ultrasound data and to display the data in B (2D), Pulsed Wave Doppler, Color Doppler, Combined (B+ Color), and M modes.
Who uses it?Intended users: healthcare professionals
What does the software produce?Output: The software automatically traces and tracks LV borders in each frame of the cardiac cycle and provides only the results for Ejection Fraction (EF), End Diastolic Volume (EDV), and End Systolic Volumes (ESV).
What is its most important limitation?Key limitation: Auto EF Quantification feature will be available on version 5.0 (Android) of Lumify Diagnostic Ultrasound System. Auto EF is a new Artificial Intelligence (AI) feature available on the S4-1 transducer in the Cardiac Preset on the Lumify application based on the LVivo EF algorithm. It provides automated assessment of the LV EF supporting evaluation from only apical four chamber (A4CH) view.
Clinical takeaway. Clinical role: Lumify is a general-purpose ultrasound system using compatible Android devices and USB transducers; K232500 adds AI-assisted automatic ejection-fraction quantification.
Evidence takeaway. Evidence from the reviewed source record: K232500 reports software, system, and feature validation supporting Auto EF and the specified Android configuration; exact feature availability differs across Android and iOS releases.
Evidence context
Evidence context not reviewed for this FDA record.
Public-label constraints
Label constraints have not been reviewed for this exact FDA record. Unknown is not all ages or evidence of unsuitability.
Public-label constraints, not patient-level eligibility or a medical recommendation. Training and evaluation populations are separate. Read the original labeling and confirm the exact release and protocol.
Purpose
Lumify is a general-purpose ultrasound system using compatible Android devices and USB transducers; K232500 adds AI-assisted automatic ejection-fraction quantification.
Exact FDA submission
Checked 2026-09-19
Clinical-use display mirrors the exact FDA-supported purpose reconciled from the decision-summary packet.
The Philips Lumify Diagnostic Ultrasound System (Lumify) is a mobile, durable, and reusable, software-controlled medical device, which is intended to acquire high-resolution ultrasound data and to display the data in B (2D), Pulsed Wave Doppler, Color Doppler, Combined (B+ Color), and M modes.
Exact FDA submission
Checked 2026-09-19
This replaces the dossier's live/imported data wording with the packet's direct acquisition and display description.
The software automatically traces and tracks LV borders in each frame of the cardiac cycle and provides only the results for Ejection Fraction (EF), End Diastolic Volume (EDV), and End Systolic Volumes (ESV).
Exact FDA submission
Checked 2026-09-19
The packet directly states the Auto EF outputs and does not state the dossier's reports output.
The packet states use in environments where healthcare is provided by healthcare professionals and does not establish the dossier's specific role list.
Auto EF Quantification feature will be available on version 5.0 (Android) of Lumify Diagnostic Ultrasound System. Auto EF is a new Artificial Intelligence (AI) feature available on the S4-1 transducer in the Cardiac Preset on the Lumify application based on the LVivo EF algorithm. It provides automated assessment of the LV EF supporting evaluation from only apical four chamber (A4CH) view.
Exact FDA submission
Checked 2026-09-19
The packet states the Android-version, transducer, and A4CH scope; it does not state the dossier's general image-quality and release-variation limitation.
K232500 reports software, system, and feature validation supporting Auto EF and the specified Android configuration; exact feature availability differs across Android and iOS releases.
Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.
Evidence summary
K232500 reports software, system, and feature validation supporting Auto EF and the specified Android configuration; exact feature availability differs across Android and iOS releases.
Sensitivity is not the primary endpoint for this acquisition, reconstruction, segmentation, guidance, or quantitative function. Use the task-specific evidence below.
Reported specificity
Not applicable
Not applicable
Not applicable
Checked 2026-09-03
Specificity is not the primary endpoint for this acquisition, reconstruction, segmentation, guidance, or quantitative function. Use the task-specific evidence below.
No contextualized exact-version metric has completed evidence review. Regulatory-document values, when available, are shown above with their limitations.
K232500 FDA performance package for Lumify Diagnostic Ultrasound System
DesignManufacturer ultrasound-system and Auto EF verification
PopulationSupported broad ultrasound applications and adult cardiac ejection-fraction workflows
Scopeexact submission
Tested versionLumify Android release with Auto EF
IndependenceSponsor or vendor study
K232500
Manufacturer evidence submitted for clearance or approval; local clinical, technical, and workflow acceptance remains necessary.
Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.
Postmarket safety review
1 reviewed FDA recall record in the 2026-09-02 openFDA snapshot natively identify K232500. Confirm affected model, version, unit, correction, and current manufacturer instructions. FDA recall Z-0883-2026 affects specified Lumify models used with Apple devices running iOS 18. Compatibility problems could prevent live imaging. FDA lists the recall as open and classified.
FDA source
Exact product version
Checked 2026-09-04
Each published event was manually matched to the exact FDA submission and affected product or version; a recall does not establish an AI-algorithm defect or current site exposure unless the event states that scope.
Exact Lumify product and native submission match; the issue is limited to specified models and the affected iOS path, while Android and Lightning-port conditions differ.
No separate named-product Medicare payment was identified in the reviewed CMS coverage material. Evaluate the product within the applicable imaging, procedural, or surgical service line and verify payer, site-of-service, and coding assumptions independently.
IT implementationDeployment, interfaces, data handling, and support
System and version relationships
Match the AI release, system build, configuration and region. Source documentation does not establish acceptance of an installed system.
No specific system/version pairing has completed review for this FDA record. A broad DICOM or product-family statement does not establish a named viewer build's support.
Public source context, not tested interoperability. Each hop needs its own release/configuration evidence. Missing or unavailable routes are not documented incompatibility. All local tests are planned, not passed; no installed-system acceptance is recorded.
Acquisition/source → routing → AI processing → returned objects → viewer/worklist/report → support owner
No specific route context has been source-reviewed for this record. Obtain both endpoint builds and documents; this is not a finding of incompatibility.
Acquisition/source
Source context, not route validation: The Philips Lumify Diagnostic Ultrasound System (Lumify) is a mobile, durable, and reusable, software-controlled medical device, which is intended to acquire high-resolution ultrasound data and to display the data in B (2D), Pulsed Wave Doppler, Color Doppler, Combined (B+ Color), and M modes.
Scope: Exact FDA submission. This replaces the dossier's live/imported data wording with the packet's direct acquisition and display description.
Confirm scanner/model, protocol, series completeness and both software builds.
Source context, not route validation: Validate supported probes and host devices, patient matching, DICOM or local export, PACS measurements, worklist, report transfer, and offline or downtime behavior.
Scope: Exact FDA submission.
Name gateways, destinations, transfer rules and failure visibility; a DICOM statement does not prove a route.
Source context, not route validation: Ultrasound hardware or software with supported probes, host devices, licensed options, and network configuration.
Scope: Exact FDA submission.
Confirm processing location, queue ownership, exclusions and exact AI build.
Source context, not route validation: The software automatically traces and tracks LV borders in each frame of the cardiac cycle and provides only the results for Ejection Fraction (EF), End Diastolic Volume (EDV), and End Systolic Volumes (ESV).
Scope: Exact FDA submission. The packet directly states the Auto EF outputs and does not state the dossier's reports output.
Confirm object classes, units, references and whether findings, overlays or measurements reach their intended destination.
Unresolved route: The software automatically traces and tracks LV borders in each frame of the cardiac cycle and provides only the results for Ejection Fraction (EF), End Diastolic Volume (EDV), and End Systolic Volumes (ESV).
Scope: Exact FDA submission. The packet directly states the Auto EF outputs and does not state the dossier's reports output.
Confirm the named viewer/worklist/report build, display behavior and report transfer. Output support alone does not establish this endpoint. The displayed source describes output, not validated end-to-end delivery.
Unresolved route: Not established for the exact route.
Scope: Scope not established.
Name the local, platform and AI supplier support owners and escalation path.
Planned local route tests
No tests below have been performed or accepted.
Patient/study identity (planned). Use approved non-patient test data to verify identifiers, accession and result-to-study linkage at every hop.
Study completeness (planned). Test missing views/series, partial transfer, late arrivals, priors and unsupported acquisition inputs; confirm explicit refusal or fallback.
Ordering and duplicates (planned). Send out-of-order, repeated and corrected studies; verify worklist order, deduplication and no misleading stale results.
Report transfer (planned). Verify output object types, annotations, units, report content, destination and availability of original images.
Access (planned). Verify authorized roles, audit trail, denied access and support ownership at each destination.
Latency and failures (planned). Agree a workload and turnaround target; test queues, timeouts, missing results and fallback reading.
Updates and rollback (planned). Define version change control, revalidation triggers, stop-use criteria and a tested rollback route.
Local implementation checklist
Agree the evidence and acceptance owner with your team and suppliers. Checkmarks apply to this page only and are not acceptance receipts.
Validate supported probes and host devices, patient matching, DICOM or local export, PACS measurements, worklist, report transfer, and offline or downtime behavior.
Philips' Responsible Disclosure Statement states that Philips maintains a global network of product security officers for developing and deploying security and privacy features for its products and services and for managing security events; that vulnerability reports to productsecurity@philips.com (PGP-encrypted) are acknowledged within two business days with a tracking number and an assigned contact; status updates approximately every 2-3 weeks; a 90-day resolution aim; and patch or advisory notification through existing customer notification processes. Vendor statement; no certification or test report was read.
Vendor-wide
Checked 2026-10-26
Vendor statement, not an attestation. Identity bridge: the statement is on philips.com (Royal Philips) and covers Philips products and services; the FDA applicant entity appears in Philips' own BCR members list on documents.philips.com (Philips Ultrasound LLC, Philips Medical Systems Nederland B.V., Philips Healthcare (Suzhou), Philips Medical Systems DMC GmbH, Philips Medical Systems Technologies Ltd., Philips Oy). Corporate policy; exact-release scope is not established.
Only qualified physicians, sonographers, and other trained ultrasound professionals. should operate or interpret the product. Local onboarding should cover the exact release, supported population, limitations, failure examples, escalation, downtime, and competency documentation.
Monitor by exact hardware, software and model version, patient population, anatomy, protocol, operator, input quality, output edits or overrides, failed studies, repeat acquisition or rework, downstream impact, downtime, incidents, recalls, and updates. Track these product-specific limits: AI-assisted measurements and views do not replace image-quality assessment or clinician interpretation; supported probes, host devices, populations, and features differ by release.
Validate supported probes and host devices, patient matching, DICOM or local export, PACS measurements, worklist, report transfer, and offline or downtime behavior.
exact submission · checked 2026-09-03
Test representative identifiers, orientation, geometry, measurements, units, routing, failure handling, and round trips locally.
Use a signed local test set for the supported population and workflow. Include common and difficult cases, exclusions, acquisition variation, failed or low-quality inputs, reviewer overrides, and downstream effects. AI-assisted measurements and views do not replace image-quality assessment or clinician interpretation; supported probes, host devices, populations, and features differ by release.
exact submission · checked 2026-09-03
Define stop-use, escalation, rollback, and revalidation triggers before production use.
Model capital and recurring cost against net staff time after review, throughput, repeat imaging or rework, room time, consumables, infrastructure, training, service, downtime, upgrade, and replacement costs.
product family · checked 2026-09-03
Vendor productivity claims are scenario inputs, not guaranteed local savings.
Monitor by exact hardware, software and model version, patient population, anatomy, protocol, operator, input quality, output edits or overrides, failed studies, repeat acquisition or rework, downstream impact, downtime, incidents, recalls, and updates. Track these product-specific limits: AI-assisted measurements and views do not replace image-quality assessment or clinician interpretation; supported probes, host devices, populations, and features differ by release.
exact submission · checked 2026-09-03
Revalidate after material software, hardware, model, protocol, interface, or clinical-policy changes.
Sources & review detailsFDA identity, research record, source ledger, and history
Regulatory identity
FDA record and catalog context
The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.
This audit distinguishes completed source review from fields that have not yet been researched.
Human reviewedStatus
2026-09-04Last searched
27Fields reviewed
12Source classes checked
0Screened PubMed leads
1Screened trial leads
0Unreviewed FDA recall leads
The refreshed discovery snapshot contains 0 PubMed and 1 ClinicalTrials.gov candidate record. Discovery metadata alone does not establish exact tested-product, version, population, and endpoint applicability, so all candidates remain quarantined and none was promoted. The current discovery snapshot contains 0 PubMed and 1 ClinicalTrials.gov candidate records; its dated, count-matched human screening remains current. Unlinked candidates remain quarantined. 1 FDA recall candidate was manually reviewed: 1 published and 0 rejected as a neighboring or otherwise inapplicable version. Native FDA recall identifiers produced 1 postmarket candidate record; 1 has been reviewed (1 published, 0 rejected) and 0 remain unreviewed.
Candidate leads were screened against the exact product and tested version. Unlinked records remain quarantined.
Source classes: fda ai list, fda decision summary, fda decision material, vendor product page, reimbursement policy, fda device recall, fda decision summary packet, literature index, trial registry, pubmed, clinical trials, openfda device recall
Field review details
Recorded state, verification date, notes and sources for fields without a publishable value. Conflicting records stay explicitly unsettled here; no plain settled value is shown for them.
Public pricing: Not publicly available - checked 2026-09-03 - Exact FDA submission
No public list price for the exact cleared configuration was found. Obtain a written quote separating hardware or license basis, enabled features, implementation, interfaces, infrastructure, training, service, upgrades, renewal, consumables, and exit costs.
GE Medical Systems Ultrasound and Primary care Diagnostics
Authorized purpose: Venue, Venue Go, Venue Fit, and Venue Sprint are general-purpose point-of-care ultrasound systems for trained users across broad adult, pediatric, and neonatal applications, with release-specific AI guidance and measurement functions.
GE Medical Systems Ultrasound and Primary Care Diagnostics
Authorized purpose: Vscan Air is a wireless handheld point-of-care ultrasound system for broad adult, pediatric, and neonatal applications. K250087 adds deep-learning automatic bladder-volume measurement and compatibility with separately cleared Caption Guidance and AutoEF functions.
GE Medical Systems Ultrasound and Primary Care Diagnostics
Authorized purpose: Versana Premier, Versana Premier Lotus, and LOGIQ F are general-purpose diagnostic ultrasound systems for broad hospital and clinic applications; K242005 adds transesophageal use, reporting and guidance tools, measurements, remote service functions, and other release-specific workflow features.
Kosmos acquires, processes, displays, measures, and stores ultrasound with synchronized ECG and digital auscultation across cardiac, lung, abdominal, vascular, musculoskeletal, and interventional applications. Adult-only Auto EF and AI FAST are adjunct functions.
Copy this public context and add the field, proposed wording and original source before sending. Nothing here is submitted automatically. Form-specific prefill has not been verified.
Permission to display a submission is not evidence verification. A submission enters editorial review; it does not approve a public change. Form availability, data entry, receipt, review and publication are separate steps. Data entry and receipt remain unverified.
Accepted repository change history
No entry has been added to this scoped change history for this record. This is not proof that the record never changed.